Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Ubiquinol, the reduced form of coenzyme Q10 (CoQ10), has been investigated as a potential adjunctive therapy for Parkinson’s Disease (PD) based on its role in mitochondrial energy production and as an antioxidant. Scientific interest stems from the observation that mitochondrial dysfunction and oxidative stress are implicated in the pathogenesis of PD. Early laboratory and animal studies suggested that CoQ10 could protect dopaminergic neurons from degeneration. This led to several clinical trials examining the efficacy of CoQ10 and ubiquinol in slowing the progression of PD.

The most notable was a large, multicenter, randomized controlled trial published in 2011 (the QE3 trial), which tested high doses of CoQ10 (up to 2400 mg/day) in early PD. Unfortunately, the study found no significant benefit over placebo in slowing disease progression. Smaller studies and pilot trials with both ubiquinone (the oxidized form) and ubiquinol have produced mixed or negative results, with most failing to show a meaningful clinical effect.

Despite the lack of clear clinical benefit, some patients and clinicians continue to use ubiquinol for its theoretical neuroprotective properties and favorable safety profile. The overall scientific evidence supporting ubiquinol for the treatment or slowing of Parkinson's Disease is weak to modest at best, which is reflected in the low evidence rating. Current guidelines do not recommend its routine use for PD.

More about ubiquinol
More about Parkinson's Disease

Other ingredients used for Parkinson's Disease

Other health conditions supported by ubiquinol

Products containing ubiquinol